| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulation, Vol 70, 271-278, Copyright © 1984 by American Heart Association
DN Sharpe, J Murphy, R Coxon and SF Hannan
A number of studies have shown short-term hemodynamic and symptomatic
improvement in patients with congestive heart failure treated with
angiotensin converting-enzyme inhibitors. The long-term efficacy of the
oral long-acting converting-enzyme inhibitor enalapril remains to be
established in controlled studies. We evaluated this drug in 36 patients
with New York Heart Association functional class II to III heart failure
who were clinically stable on digoxin and diuretic therapy. After baseline
assessment of symptoms, exercise capacity, and results of echocardiographic
examination and right heart catheterization, patients were randomly
assigned to treatment with 5 mg enalapril twice daily (n = 18) or placebo
(n = 18) in a double-blind fashion. The two groups had similar clinical,
echocardiographic, and hemodynamic characteristics before treatment. After
3 months of treatment, the enalapril group showed a significant improvement
as judged by subjective patient impression, functional class, and exercise
duration (9.3 +/- 5.7 vs 17.6 +/- 5.6 min; p less than .001). Diuretic
dosage was reduced in six patients and increased in one patient, one
patient had died and another had been withdrawn from the study. In the
placebo group there was no significant change with respect to patient
impression, functional class, or exercise duration; diuretic dosage was
increased in seven patients and four patients had died. Echocardiographic
left ventricular dimensions were significantly reduced and left ventricular
shortening fraction significantly increased in the enalapril group but were
unchanged in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study
This article has been cited by other articles:
 |
|
 |
|
  A. Dore, C. Houde, K.-L. Chan, A. Ducharme, P. Khairy, M. Juneau, F. Marcotte, and L.-A. Mercier Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles: A Multicenter, Randomized, Placebo-Controlled Clinical Trial Circulation, October 18, 2005; 112(16): 2411 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation, September 20, 2005; 112(12): 1825 - 1852. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Adler, E. Messina, B. Sherman, Z. Wang, H. Huang, A. Linke, and T. H. Hintze NAD(P)H oxidase-generated superoxide anion accounts for reduced control of myocardial O2 consumption by NO in old Fischer 344 rats Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1015 - H1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure Arch Intern Med, March 12, 2001; 161(5): 667 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Nanas, G. Alexopoulos, M. I. Anastasiou-Nana, K. Karidis, A. Tirologos, S. Zobolos, V. Pirgakis, L. Anthopoulos, D. Sideris, S. F. Stamatelopoulos, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2090 - 2095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Forfia, X. Zhang, D. R. Knight, A. H. Smith, C. P. A. Doe, E. A. Wolfgang, D. M. Flynn, M. S. Wolin, and T. H. Hintze NO modulates myocardial O2 consumption in the nonhuman primate: an additional mechanism of action of amlodipine Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2069 - H2075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Abraham Pharmacologic Management of Chronic Heart Failure: A Review Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 168 - 190. [Abstract] [PDF]
|
|
|
|
|
|
Effects of Carvedilol, a Vasodilator–ß-Blocker, in Patients With Congestive Heart Failure Due to Ischemic Heart Disease Circulation, July 15, 1995; 92(2): 212 - 218. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Munger, S. F. Gardner, and R. C. Jarvis Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Journal of Pharmacy Practice, January 1, 1990; 3(5): 318 - 331. [Abstract] [PDF]
|
|